pCR: hormone receptor‐positive · neoadjuvant treatment of ER‐positive vs ER‐negative breast cancer
Capecitabine‐containing regimens showed no clear difference in pCR: hormone receptor‐positive compared with non‐capecitabine‐containing regimens (moderate certainty).
1 finding from 1 review
pCR: hormone receptor‐negative · neoadjuvant treatment of ER‐positive vs ER‐negative breast cancer
Capecitabine‐containing regimens showed no clear difference in pCR: hormone receptor‐negative compared with non‐capecitabine‐containing regimens (moderate certainty).
1 finding from 1 review
Disease-free survival · neoadjuvant treatment of ER‐positive vs ER‐negative breast cancer
Capecitabine‐containing regimens showed no clear difference in disease‐free survivalmedian compared with non‐capecitabine‐containing regimens (high certainty).
1 finding from 1 review
Overall survivalmedian · neoadjuvant treatment of ER‐positive vs ER‐negative breast cancer
Capecitabine‐containing regimens showed no clear difference in overall survivalmedian compared with non‐capecitabine‐containing regimens (high certainty).
1 finding from 1 review
Febrile neutropenia · neoadjuvant treatment of ER‐positive vs ER‐negative breast cancer
Capecitabine‐containing regimens showed no clear difference in febrile neutropenia compared with non‐capecitabine‐containing regimens (moderate certainty).
1 finding from 1 review
Diarrhoea · neoadjuvant treatment of ER‐positive vs ER‐negative breast cancer
Capecitabine‐containing regimens probably leads to higher diarrhoea compared with non‐capecitabine‐containing regimens (moderate certainty).
1 finding from 1 review
Hand‐foot syndrome · neoadjuvant treatment of ER‐positive vs ER‐negative breast cancer
Capecitabine‐containing regimens probably leads to higher hand‐foot syndrome compared with non‐capecitabine‐containing regimens (moderate certainty).
1 finding from 1 review
Disease-free survival · patients with early breast cancer
Capecitabine‐containing regimens showed no clear difference in disease‐free survival (DFS)median compared with non‐capecitabine‐containing regimens or no chemotherapy (moderate certainty).
1 finding from 1 review
DFS: hormone receptor‐positivemedian · patients with early breast cancer
Capecitabine‐containing regimens showed no clear difference in DFS: hormone receptor‐positivemedian compared with non‐capecitabine‐containing regimens or no chemotherapy (moderate certainty).
1 finding from 1 review
DFS: hormone receptor‐negativemedian · patients with early breast cancer
Capecitabine‐containing regimens probably leads to lower DFS: hormone receptor‐negativemedian compared with non‐capecitabine‐containing regimens or no chemotherapy (moderate certainty).
1 finding from 1 review
Overall survival: Median length of · patients with early breast cancer
Capecitabine‐containing regimens probably leads to lower overall survival (OS)median compared with non‐capecitabine‐containing regimens or no chemotherapy (moderate certainty).
1 finding from 1 review
Febrile neutropenia · patients with early breast cancer
Capecitabine‐containing regimens probably leads to lower febrile neutropenia compared with non‐capecitabine‐containing regimens or no chemotherapy (moderate certainty).
1 finding from 1 review
Diarrhoea · patients with early breast cancer
Capecitabine‐containing regimens probably leads to higher diarrhoea compared with non‐capecitabine‐containing regimens or no chemotherapy (moderate certainty).
1 finding from 1 review
Hand‐foot syndrome · patients with early breast cancer
Capecitabine‐containing regimens probably leads to higher hand‐foot syndrome compared with non‐capecitabine‐containing regimens or no chemotherapy (moderate certainty).
1 finding from 1 review
Pathological complete response · neoadjuvant treatment of ER‐positive vs ER‐negative breast cancer
Capecitabine‐containing regimens showed no clear difference in pathological complete response (pCR): breast and axillary nodes compared with non‐capecitabine‐containing regimens (high certainty).
1 finding from 1 review
Overall survival: Median length of · people with metastatic breast cancer
Capecitabine‐containing regimens showed no clear difference in overall survival (OS)median compared with chemotherapy regimens without capecitabine (high certainty).
1 finding from 1 review
OS: hormone receptor‐positivemedian · people with metastatic breast cancer
Capecitabine‐containing regimens showed no clear difference in OS: hormone receptor‐positivemedian compared with chemotherapy regimens without capecitabine (high certainty).
1 finding from 1 review
OS: hormone receptor‐negativemedian · people with metastatic breast cancer
Capecitabine‐containing regimens showed no clear difference in OS: hormone receptor‐negativemedian compared with chemotherapy regimens without capecitabine (high certainty).
1 finding from 1 review
Progression‐free survival · people with metastatic breast cancer
Capecitabine‐containing regimens probably leads to lower progression‐free survival (PFS)median compared with chemotherapy regimens without capecitabine (moderate certainty).
1 finding from 1 review
PFS: hormone receptor‐positivemedian · people with metastatic breast cancer
Capecitabine‐containing regimens probably leads to lower PFS: hormone receptor‐positivemedian compared with chemotherapy regimens without capecitabine (moderate certainty).
1 finding from 1 review